Market revenue in 2023 | USD 168.0 million |
Market revenue in 2030 | USD 240.9 million |
Growth rate | 5.3% (CAGR from 2023 to 2030) |
Largest segment | Purity>98% |
Fastest growing segment | Purity>98% |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Purity>98%, Purity<98% |
Key market players worldwide | Merck KGaA, GSK PLC, Cipla Ltd DR, Novartis AG ADR, Sanofi SA, Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Mallinckrodt PLC Ordinary Shares - New, Cayman Chemical, Tokyo Chemical Industry, APExBIO Technology, Wilshire Technologies, Biosynth |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to crocin market will help companies and investors design strategic landscapes.
Purity>98% was the largest segment with a revenue share of 95.48% in 2023. Horizon Databook has segmented the China crocin market based on purity>98%, purity<98% covering the revenue growth of each sub-segment from 2018 to 2030.
China is a major global producer and exporter of paracetamol API, exporting large amounts each year. Its paracetamol export volume increased significantly from 2018 to 2020. China exported paracetamol to over 100 countries and regions worldwide.
It is estimated that Thailand, Indonesia, the Russian Federation, Vietnam, Egypt, France, Bangladesh, Ireland, and Brazil are the major export destinations of paracetamol from China by export volume. Indonesia is the most important destination for Chinese paracetamol exports.
In China, in the end of December 2022, daily production and supply of paracetamol & ibuprofen have more than quadrupled since early December 2022, with daily production now exceeding 190 million tablets. However, the country experienced a shortage of fever-suppressing drugs as COVID-19 incidence increased following the government’s rapid dismantlement of its zero-COVID-19 measures in early December 2022.
Horizon Databook provides a detailed overview of country-level data and insights on the China crocin market , including forecasts for subscribers. This country databook contains high-level insights into China crocin market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account